Results 51 to 60 of about 1,128 (166)

Cyclosporine nephrotoxicity

open access: yesCleveland Clinic Journal of Medicine, 1989
Cyclosporine is a potent and useful immunosuppressive agent used primarily in conjunction with solid organ transplantation. The most serious adverse reaction that limits its use is nephrotoxicity due to effects on the renal vasculature, glomeruli, and tubular function. These effects result in a variety of clinical syndromes.
openaire   +2 more sources

Serum Eosinophil‐Derived Neurotoxin (EDN) as a Biomarker for Treatment Response in Atopic Dermatitis

open access: yes
Clinical &Experimental Allergy, EarlyView.
J. I. Olydam   +3 more
wiley   +1 more source

A primary cell‐based fluidic co‐culture model to investigate drug transport across the human placenta

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Schematic overview of a flow‐driven in vitro model of the human placental barrier designed to study transport processes during pregnancy. The model recreates key features of the maternal–fetal interface, enabling the investigation of how nutrients and therapeutic compounds cross the placental barrier under physiologically ...
Barbara Fuenzalida   +7 more
wiley   +1 more source

SARS‐CoV‐2 targets mitochondria, exacerbating COVID‐19 pneumonia

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Following entry into airway epithelial cells (AECs), SARS‐CoV‐2 releases its single‐stranded RNA into the cytoplasm, where it is translated into viral proteins. Several of these viral proteins localize to mitochondria and interact with key mitochondrial components.
Danchen Wu   +5 more
wiley   +1 more source

Next Generation Hosts for Protein Recognition, Assembly and More

open access: yesChemistry – A European Journal, Volume 32, Issue 30, 13 August 2026.
The original design of synthetic receptors for proteins was based on macrocycles with a hydrophobic core and a polar/charged periphery. This design, geared towards protein recognition, facilitates receptor self‐assembly. Macrocycle oligomerization, in turn, contributes to protein assembly as evidenced in many cocrystal structures.
Peter B. Crowley
wiley   +1 more source

Better 10‐Year Cerebrovascular Outcome After Transplant Than on Standard‐Care in Sickle Cell Anemia: DREPAGREFFE Trial

open access: yesAmerican Journal of Hematology, Volume 101, Issue 8, Page 1799-1817, August 2026.
ABSTRACT Management of cerebral vasculopathy in sickle cell anemia (SCA) includes standard‐care, that is, chronic transfusion (CT) or hydroxyurea, and hematopoietic cell transplantation (HCT). DREPAGREFFE‐1 (December 2010/June 2013), a French multicenter trial, was the first prospective trial comparing standard‐care to match sibling donor (MSD)‐HCT in ...
Francoise Bernaudin   +40 more
wiley   +1 more source

Humoral and cellular responses to SARS‐CoV‐2 variants after ancestral COVID‐19 vaccines in people with HIV and lung transplant recipients

open access: yesClinical &Translational Immunology, Volume 15, Issue 8, 2026.
This study compares the humoral and cellular immunogenicity of Dose 3 of Ancestral SARS‐CoV‐2 vaccine in participants with HIV and/or following lung transplantation with healthy controls. We highlight differences along a spectrum of immunocompromise, and the value of SARS‐CoV‐2 vaccination, even in the absence of detectable neutralisation responses ...
David WJ Griffin   +15 more
wiley   +1 more source

What Is Your Diagnosis? Cutaneous Mass in a Dog

open access: yes
Veterinary Clinical Pathology, EarlyView.
Ester Quilez, Shannon L. Donahoe
wiley   +1 more source

Tacrolimus Bridging and Combination Therapy Following Infliximab and JAK Inhibitor Failure in Ulcerative Colitis: A Case Series

open access: yesJGH Open, Volume 10, Issue 8, August 2026.
ABSTRACT Background Calcineurin inhibitors such as tacrolimus are established rescue therapies for steroid‐refractory ulcerative colitis (UC). However, their efficacy and safety as bridging or combination therapy following failure of both anti‐tumor necrosis factor (anti‐TNF) and Janus kinase (JAK) inhibitor therapy remain uncertain.
Nikil Vootukuru   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy